Details

Autor(en) / Beteiligte

• Zhang, Xueyang
• Bai, Ran
• Jia, Yong
• Zong, Junwei
• Wang, Yongbo
• Dong, Yanan

Titel

The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus

Ist Teil von

• International journal of diabetes in developing countries, 2020-10, Vol.40 (4), p.491-499

Ort / Verlag

New Delhi: Springer India

Erscheinungsjahr

2020

Quelle

AUTH Library subscriptions: Springer Journals

Beschreibungen/Notizen

• Aims The objective is to investigate the effects of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus. Materials and methods Thirty-two patients with T2DM and NAFLD admitted to the Third Affiliated Hospital of Dalian Medical University from December 2014 to December 2016 were selected, including 11 females and 21 males, aged 39.34 ± 8.54 years old. The patients were given liraglutide on the basis of their original hypoglycemic regimen. Results After 3 months treatment of liraglutide, FPG was reduced from 8.54 ± 2.21 mmol/L to 6.90 ± 1.73 mmol/L. HbA1c was reduced from 9.72 ± 1.95 to 7.78 ± 1.99. WC was reduced from 103.27 ± 9.92 kg to 93.97 ± 8.35 kg. BMI was reduced from 30.56 ± 4.06 kg/m 2 to 28.01 ± 3.12 kg/m 2 . FLI was reduced from 79.23 ± 16.56 to 58.83 ± 19.75. The differences were statistically significant ( p  < 0.001). TG was reduced from 2.95 ± 2.13 mmol/L to 2.27 ± 1.31 mmol/L. The difference was significant ( p  < 0.01). Meanwhile, HOMA-IR was reduced from 1.504 ± 0.002 to 1.503 ± 0.002. GGT was reduced from 62.63 ± 71.61 U/L to 38.13 ± 30.13 U/L. AST was reduced from 27.25 ± 13.74 U/L to 25.44 ± 16.69 U/L. The differences were statistically significant ( p  < 0.05). After treatment, FCP, TC, HDL-C, LDL-C, ALT, and HOMA-β were also improved compared with before treatment, but the difference was not statistically significant ( p  > 0.05). Conclusion In addition to effectively lowering glucose and improving islet resistance, liraglutide could also improve obesity and adjust blood lipids. However, the improvement of islet function might not be significant after 3 months of treatment. Liraglutide could reduce liver fat accumulation in patients with T2DM and NAFLD.